New study asks: is this glucose monitor a Game-Changer for diabetes?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects to provide written informed consent prior to any study procedures being performed * Subjects with age 18 and above both male and female * Diagnosed with Diabetes Miletus Type I, Type II and/or GDM * Comfortable using smart phone, access to internet along with Bluetooth connectivity throughout the study duration. * Subjects (Patients) on oral or injectable anti-diabetic medications, (in case of insulin, patient must be on insulin from last 3 months ) * Subjects (HCPs) healthy, Pre-diabetes or Diabetes Miletus (any type) Exclusion Criteria: * History of hypersensitivity to any of the active or inactive ingredients of the CGM device used in the trial, and/or history of significant allergic skin reactions. * Presence of severe diabetes complications e.g. retinopathy, acute metabolic crisis, etc. * History of active/ acute renal and/or hepatic failure. * Patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state. * History of critical illness or incapacitated patients * History of acute psychiatric disorder or exacerbation of chronic psychiatric disorder. * History or presence of a medical condition or disease that in the investigator's opinion would embarrass glycemic control and completion of the study. * Medical conditions that require patients to undergo frequent radiation/ imaging procedures for example CT, MRI and X rays * History of known hematological disorders such as Sickle Cell Disease \& Trait, Thalassemia, Hemolytic Anemias (e.g., G6PD deficiency, autoimmune), Iron Deficiency Anemia * Patients on high doses of acetaminophen (\>1 gram every 6 hours), ascorbic acid supplements (e.g., \> 500-1000 mg/day), IV sorbitol, steroids and aspirin which can alter the readings on the CGM device.